New stroke drug aims to cut disability in first 3 hours
Disease control
Recruiting now
This phase 3 trial tests whether a single injection of BXOS110, given within 3 hours of an acute ischemic stroke, can reduce overall disability compared to a placebo. About 1112 adults aged 18-85 with moderate to severe stroke are being enrolled. The main goal is to see if more p…
Phase: PHASE3 • Sponsor: Biocells (Beijing) Biotech Co.,Ltd • Aim: Disease control
Last updated Jun 24, 2026 07:05 UTC